NMP22 test

NMP22® test

Urology A urine assay for identifying Pts at risk for recurrent bladder CA; Pts with high NMP22–nuclear matrix protein levels 10 days post-surgery tend to have recurrent CA within 3 months. See Bladder cancer.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
However, many researchers underline the higher diagnostic value of the NMP22 test than cytology particularly for the T stage and G grade.
A routine cytologic examination and NMP22 test were performed on the voided urine sample that was provided before the cystoscopy.
In this study, we demonstrate that high-risk patients with negative cystoscopy on surveillance, but positive urine NMP22, have a higher rate of recurrence and reduced recurrence-free survival time in comparison to patients who have a negative NMP22 test. In contrast, there was no evidence to suggest that urine cytology has the same predictive capability.
The NMP22 test has a highly variable reported sensitivity and specificity.
The investigators compared the NMP22 test results with cytology results, with cystoscopy as the reference standard.
In an interview, he said the NMP22 test is ideal for general practitioners because they can pretty well rule out bladder cancer if it is negative.
The NMP22 Test Kit is cleared for marketing in the United States for management and screening of individuals at risk of bladder cancer.
Several studies reported sensitivities for the NMP22 test ranging from 68% [12] to l00%, [13] without significant differences.
The NMP22 test (NMP22[R] Test Kit; Matritech, Inc.) is an enzyme immunoassay that detects the NMP complexes, specifically NMP22.
(Newton, MA; 617-928-0820), a company specializing in products designed to manage and screen cancer, announced that it has been issued United States Patent 5,882,876 by the United States Patent and Trademark Office for its invention using a nuclear matrix protein in Matritech's urine-based NMP22 Test Kit for bladder cancer.